A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma
KCP-330-017 (STOMP)
NCT02343042
 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Myeloma |
Dr. Marc Lalancette
Diane Bernard
418-525-4444 poste 15782
Patricia Chabot
418-525-4444 poste 15769
|
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
NCI M4
NCT03421132
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Nathalie Lachapelle
514-252-3400 poste 4471
|
A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Nathalie Lachapelle
514-252-3400 poste 4471
|
A phase 1B, open-label study of Elranatamab in combination with Iberdomide in participants with relapsed refractory multiple myeloma
MagnetisMM-30 (C1071030)
NCT06215118
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Myeloma |
Dr. Michel Pavic
Christine Lawson
819-346-1110 poste 12942
|
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
CARTITUDE-6
NCT05257083
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
QUINTESSENTIAL
NCT06297226
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Lmmunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma
D7230C00001
NCT06106945
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
EXCALIBER-Maintenance
NCT05827016
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Myeloma |
Dr. Marc Lalancette
Philippe Nadeau
418-649-0252 poste 63115
|
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
CARTITUDE-6
NCT05257083
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Myeloma |
Dr. Marc Lalancette
Philippe Nadeau
418-649-0252 poste 63115
|
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
MajesTEC-7
NCT05552222
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Myeloma |
Dr. Marc Lalancette
Patricia Chabot
415-525-4444 poste 15768
|
Groupe d'étude en oncologie du Québec